A Randomized Phase II Study of Intermittent chemotherapy or Intermittent Chemotherapy with maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer
The purpose of this study is to see what effects GM-CSF, the study drug, has on prostate cancer in subjects who are on an intermittent chemotherapy schedule with docetaxel (Taxotere).
* Subjects should have documented prostate cancer that has spread outside the prostate and is no longer responding to hormone therapy.
* Subjects may have up to 3 cycles of prior docetaxel chemotherapy before enrollment
* Subject should not have prior immunotherapy including systemic GM-CSF or vaccines utilizing GM-CSF
18 - 100
Healthy Volunteers Needed
Duration of Participation
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com